Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliografía
[1.]
H. Fleisch.
Biphosphonates: Mechanism of action.
Endocr Rev, (1998), 19 pp. 80-100
[2.]
S.P. Luckman, D.E. Hughes, F.P. Coxon, R. Graham, G. Russell, M.J. Rogers.
Nitrogen containing bisphosphonates inhibit the mevalonate pathway and prevent post translational prenilation of GTP binding proteins, including Ras.
J Bone Miner Res, (1998), 13 pp. 581-589
[3.]
M. Vitale, T. Di Matola, G. Rossi, C. Laezza, G. Fenzi, M. Bifulco.
Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent CrmA-sensitive, and caspase-3-like protease-dependent mechanism.
Endocrinology, (1999), 140 pp. 698-704
[4.]
Y. Abe, A. Kawakami, T. Nakashima, E. Ejima, K. Fujiyama, T. Kiriyama, et al.
Etidronate inhibits human osteoblast apoptosis by inhibition of pro-apoptotic factor(s) produced by activated T cells.
J Lab Clin Med, (2000), 136 pp. 344-354
[5.]
G.H. Nancollas, R. Tang, R.J. Phipps, Z. Henneman, S. Gulde, W. Wu, et al.
Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.
Bone, (2006), 38 pp. 617-627
[6.]
K.L. Kavanagh, K. Guo, J.E. Dunford, X. Wu, S. Knapp, F.H. Ebetino, et al.
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.
Proc Natl Acad Sci U S A, (2006), 103 pp. 7829-7834
[7.]
A. Cranney, G. Guyatt, N. Krolicki, V. Welch, L. Griffith, J.D. Adachi, et al.
A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis.
Osteoporos Int, (2001), 12 pp. 140-151
[8.]
S. Adami, V. Bruni, D. Bianchini, A. Becorpi, P. Lombardi, C. Campagnoli, et al.
Prevention of early postmenopausal bone loss with cyclical etidronate.
J Endocrinol Invest, (2000), 23 pp. 310-316
[9.]
K. Kitatani, K. Nakatsuka, H. Naka, T. Miki, H. Morii, Y. Nishizawa.
Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy.
J Bone Miner Metab, (2003), 21 pp. 217-224
[10.]
S.L. Greenspan, D.L. Schneider, M.R. McLung, P.D. Miller, T.J. Schnitzer, R. Bonin, et al.
Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities.
Ann Intern Med, (2002), 136 pp. 742-746
[11.]
H.G. Bone, D. Hosking, J.P. Devogelaer, J.R. Tucci, R.D. Emkey, R.P. Tonino, et al.
Ten years’ experience with alendronate for osteoporosis in postmenopausal women.
N Engl J Med, (2004), 350 pp. 1189-1199
[12.]
T. Schnitzer, H.G. Bone, G. Crepaldi, S. Adami, M. McClung, D. Kiel, et al.
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Aging (Milano), (2000), 12 pp. 1-12
[13.]
R. Rizzoli, S.L. Greenspan, G. Bone 3rd, T.J. Schnitzer, N.B. Watts, S. Adami, et al.
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
J Bone Miner Res, (2002), 17 pp. 1988-1996
[14.]
M.M. Luckey, N. Gilchrist, H.G. Bone, M.W. Davie, T.J. de Villiers, M. Wu, et al.
Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis.
Obstet Gynecol, (2003), 101 pp. 711-721
[15.]
H.G. Bone, R.W. Downs Jr, J.R. Tucci, S.T. Harris, R.S. Weinstein, et al.
Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.
J Clin Endocrinol Metab, (1997), 82 pp. 265-274
[16.]
Y.Z. Bagger, L.B. Tanko, P. Alexandersen, P. Ravn, C. Christiansen.
Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal.
Bone, (2003), 33 pp. 301-307
[17.]
K.E. Ensrud, E.L. Barrett-Connor, A. Schwartz, A.C. Santora, D.C. Bauer, S. Suryawanshi, et al.
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
J Bone Miner Res, (2004), 19 pp. 1259-1269
[18.]
N.H. Bell, J.P. Bilezikian, H.G. Bone 3rd, A. Kaur, A. Maragoto, A.C. Santora, et al.
Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women.
J Clin Endocrinol Metab, (2002), 87 pp. 2792-2797
[19.]
L.O. Chailurkit, W. Jongjaroenprasert, S. Rungbunnapun, B. Ongphiphadhanakul, S. Sae-tung, R. Rajatanavin.
Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis.
J Bone Miner Metab, (2003), 21 pp. 421-427
[20.]
D.M. Black, D.E. Thompson, D.C. Bauer, K. Ensrud, T. Musliner, M.C. Hochberg, et al.
Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.
J Clin Endocrinol Metab, (2000), 85 pp. 4118-4124
[21.]
S.A. Quandt, D.E. Thompson, D.L. Schneider, M.C. Nevitt, D.M. Black, Fracture Intervention Trial Research Group.
Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial.
Mayo Clin Proc, (2005), 80 pp. 343-349
[22.]
A. Cranney, G. Wells, A. Willan, L. Griffith, N. Zytaruk, V. Robinson, et al.
Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.
Endocr Rev, (2002), 23 pp. 508-516
[23.]
S. Boonen, R.F. Laan, I.P. Barton, N.B. Watts.
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
Osteoporos Int, (2005), 16 pp. 1291-1298
[24.]
S.E. Papapoulos, S.A. Quandt, U.A. Liberman, M.C. Hochberg, D.E. Thompson.
Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women.
Osteoporos Int, (2005), 16 pp. 468-474
[25.]
K.G. Saag, R. Emkey, T.J. Schnitzer, J.P. Brown, F. Hawkins, S. Goemaere, et al.
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
N Engl J Med, (1998), 339 pp. 292-299
[26.]
R. Emkey, P.D. Delmas, S. Goemaere, U.A. Liberman, P.E. Poubelle, A.G. Daifotis, et al.
Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
Arthritis Rheum, (2003), 48 pp. 1102-1108
[27.]
E. Orwoll, M. Ettinger, S. Weiss, P. Miller, D. Kendler, J. Graham, et al.
Alendronate for the treatment of osteoporosis in men.
N Engl J Med, (2000), 343 pp. 604-610
[28.]
J.D. Ringe, H. Faber, A. Dorst.
Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study.
J Clin Endocrinol Metab, (2001), 86 pp. 5252-5255
[29.]
J.D. Ringe, A. Dorst, H. Faber, K. Ibach.
Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study.
Rheumatol Int, (2004), 24 pp. 110-113
[30.]
J.S. Finkelstein, A. Hayes, J.L. Hunzelman, J.J. Wyland, H. Lee, R.M. Neer.
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
N Engl J Med, (2003), 349 pp. 1216-1226
[31.]
S. Gonnelli, C. Cepollaro, A. Montagnani, D. Bruni, C. Caffarelli, M. Breschi, et al.
Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study.
Calcif Tissue Int, (2003), 73 pp. 133-139
[32.]
P.D. Miller, T. Schnitzer, R. Emkey, E. Orwoll, C. Rosen, M. Ettinger, et al.
Weekly oral alendronic acid in male osteoporosis.
Clin Drug Investig, (2004), 24 pp. 333-341
[33.]
I. Shimon, V. Eshed, R. Doolman, B.A. Sela, A. Karasik, I. Vered.
Alendronate for osteoporosis in men with androgen-repleted hypogonadism.
Osteoporos Int, (2005), 16 pp. 1591-1596
[34.]
I. Fogelman, C. Ribot, R. Smith, D. Ethgen, E. Sod, J.Y. Reginster.
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MNStudy Group.
J Clin Endocrinol Metab, (2000), 85 pp. 1895-1900
[35.]
J.P. Brown, D.L. Kendler, M.R. McClung, R.D. Emkey, J.D. Adachi, M.A. Bolognese, et al.
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
Calcif Tissue Int, (2002), 71 pp. 103-111
[36.]
S.T. Harris, N.B. Watts, Z. Li, A.A. Chines, D.A. Hanley, J.P. Brown.
Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.
Curr Med Res Opin, (2004), 20 pp. 757-764
[37.]
J.Y. Leung, A.Y. Ho, T.P. Ip, G. Lee, A.W. Kung.
The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study.
Bone, (2005), 36 pp. 358-364
[38.]
L. Raisz, J.A. Smith, M. Trahiotis, P. Fall, K. Shoukri, J. Digennaro, et al.
Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover.
Osteoporos Int, (2000), 11 pp. 615-620
[39.]
S.T. Harris, N.B. Watts, H.K. Genant, C.D. McKeever, T. Hangartner, M. Keller, et al.
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
JAMA, (1999), 282 pp. 1344-1352
[40.]
J. Reginster, H.W. Minne, O.H. Sorensen, M. Hooper, C. Roux, M.L. Brandi, et al.
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
Osteoporos Int, (2000), 11 pp. 83-91
[41.]
A. Cranney, J.D. Adachi, G. Guyatt, A. Papaioannou, V.A. Robinson, B.J. Shea, et al.
Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cochrane Database Syst Rev, (2007), 1
[42.]
A. Cranney, P. Tugwell, J. Adachi, B. Weaver, N. Zytaruk, A. Papaioannou, et al.
Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.
Endocr Rev, (2002), 23 pp. 517-523
[43.]
M.R. McClung, P. Geusens, P.D. Miller, H. Zippel, W.G. Bensen, C. Roux, et al.
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
N Engl J Med, (2001), 344 pp. 333-340
[44.]
O.H. Sorensen, G.M. Crawford, H. Mulder, D.J. Hosking, C. Gennari, D. Mellstrom, et al.
Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience.
Bone, (2003), 32 pp. 120-126
[45.]
D.D. Mellstrom, O.H. Sorensen, S. Goemaere, C. Roux, T.D. Johnson, A.A. Chines.
Seven years of treatment with risedronate in women with postmenopausal osteoporosis.
Calcif Tissue Int, (2004), 75 pp. 462-468
[46.]
S. Wallach, S. Cohen, D.M. Reid, R.A. Hughes, D.J. Hosking, R.F. Laan, et al.
Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
Calcif Tissue Int, (2000), 67 pp. 277-285
[47.]
D.M. Reid, S. Adami, J.P. Devogelaer, A.A. Chines.
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
Calcif Tissue Int, (2001), 69 pp. 242-247
[48.]
D.M. Reid, R.A. Hughes, R.F. Laan, N.A. Sacco-Gibson, D.H. Wenderoth, S. Adami, et al.
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
J Bone Miner Res, (2000), 15 pp. 1006-1013
[49.]
R. Eastell, J.P. Devogelaer, N.F. Peel, A.A. Chines, D.E. Bax, N. Sacco-Gibson, et al.
Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients.
Osteoporos Int, (2000), 11 pp. 331-337
[50.]
J.D. Ringe, P. Farahmand, H. Faber, A. Dorst.
Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
Rheumatol Int, (2009), 29 pp. 311-315
[51.]
C.H. Chesnut III, A. Skag, C. Christiansen, R. Recker, J.A. Stakkestad, A. Hoiseth, et al.
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
J Bone Miner Res, (2004), 19 pp. 1241-1249
[52.]
P.D. Miller, M.R. McClung, L. Macovei, J.A. Stakkestad, M. Luckey, B. Bonvoisin, et al.
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
J Bone Miner Res, (2005), 20 pp. 1315-1322
[53.]
P.D. Delmas, R.R. Recker, C.H. Chesnut 3rd, A. Skag, J.A. Stakkestad, R. Emkey, et al.
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.
Osteoporos Int, (2004), 15I 10 pp. 792-798
[54.]
L.B. Tanko, U. Mouritzen, H.J. Lehmann, L. Warming, A. Moelgaard, S. Christgau, et al.
Oral ibandronate: changes in markers of bone turn-over during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens.
Bone, (2003), 32 pp. 687-693
[55.]
C.H. Chesnut, M.P. Ettinger, P.D. Miller, D.J. Baylink, R. Emkey, S.T. Harris, et al.
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.
Curr Med Res Opin, (2005), 21 pp. 391-401
[56.]
S.T. Harris, W.A. Blumentals, P.D. Miller.
Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies.
Curr Med Res Opin, (2008), 24 pp. 237-245
[57.]
A. Cranney, G.A. Wells, E. Yetisir, S. Adami, C. Cooper, P.D. Delmas, et al.
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data.
Osteoporos Int, (2009), 20 pp. 291-297
[58.]
J.A. Stakkestad, P. Lakatos, R. Lorenc, F. Sedarati, C. Neate, J.Y. Reginster.
Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension.
Clin Rheumatol, (2008), 27 pp. 955-960
[59.]
O. Lamy, L. Sandini, I. Pache, S. Fatio, J. Burnand, P. Burckhardt.
Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years.
J Endocrinol Invest, (2003), 26 pp. 728-732
[60.]
Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G. Efficacy and safety of monthly ibandronate in men with low bone density. Bone. 2010. En prensa.
[61.]
I.R. Reid, J.P. Brown, P. Burckhardt, Z. Horowitz, P. Richardson, U. Trechsel, et al.
Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
NEngl J Med, (2002), 346 pp. 653-661
[62.]
D.M. Black, P.D. Delmas, R. Eastell, I.R. Reid, S. Boonen, J.A. Cauley, et al.
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
NEngl J Med, (2007), 356 pp. 1809-1822
[63.]
K.W. Lyles, C.S. Colon-Emeric, J.S. Magaziner, J.D. Adachi, C.F. Pieper, C. Mautalen, et al.
Zoledronic acid and clinical fractures and mortality after hip fracture.
NEngl J Med, (2007), 357 pp. 1799-1809
[64.]
D.M. Reid, J.P. Devogelaer, K. Saag, C. Roux, C.S. Lau, J.Y. Reginster, et al.
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, dou-ble-blind, double-dummy, randomised controlled trial.
Lancet, (2009), 373 pp. 1253-1263
[65.]
F. Lanza, B. Sahba, H. Schwartz, S. Winograd, J. Torosis, H. Quan, et al.
The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study.
Am J Gastroenterol, (2002), 97 pp. 58-64
[66.]
F.L. Lanza, M.F. Rack, Z. Li, S.A. Krajewski, M.A. Blank.
Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women.
Aliment Pharmacol Ther, (2000), 14 pp. 1663-1670
[67.]
M. Sosa Henríquez, M.J. Gómez de Tejada Romero, J.V. Bagán Sebastián, M. Díaz Curiel, A. Díez Pérez, E. Jodar-Gimeno, et al.
Osteonecrosis de los maxilares: Documento de consenso.
Rev Osteoporos Metab Miner, (2009), 1 pp. 41-51
[68.]
S.R. Heckbert, G. Li, S.R. Cummings, N.L. Smith, B.M. Psaty.
Use of alendronate and risk of incident atrial fibrillation in women.
Arch Intern Med, (2008), 168 pp. 826-831
[69.]
Kim SY, Solomon DH. Bisphosphonates and risk of atrial fibrillation: a meta-analysis. ACR/ARHP Scientific Meeting 2009 (November).
[70.]
C.V. Odvina, J.E. Zerwekh, D.S. Rao, N. Maalouf, F.A. Gottschalk, C.Y. Pak.
Severely suppressed bone turnover: a potential complication of alendronate therapy.
J Clin Endocrinol Metab, (2005), 90 pp. 1294-1301
[71.]
Breglia MD, Carter JD. Atypical Insufficiency fracture of the tibia associated with long-term bisphosphonate therapy. J Clin Rheumatol. 2010. En prensa.
Copyright ©
2010. Elsevier España, S.L.. Todos los derechos reservados
